Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $25,764.75 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Rating) CEO James F. Oliviero III sold 3,817 shares of the stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $6.75, for a total transaction of $25,764.75. Following the completion of the sale, the chief executive officer now directly owns 192,382 shares of the company’s stock, valued at approximately $1,298,578.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Checkpoint Therapeutics Stock Performance

Shares of CKPT stock opened at $7.60 on Friday. The firm’s 50 day moving average price is $3.16 and its 200-day moving average price is $1.84. Checkpoint Therapeutics, Inc. has a one year low of $3.56 and a one year high of $27.00. The firm has a market cap of $70.68 million, a P/E ratio of -0.87 and a beta of 1.54.

Checkpoint Therapeutics (NASDAQ:CKPT – Get Rating) last released its earnings results on Tuesday, November 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.07 million. Checkpoint Therapeutics had a negative net margin of 53,252.24% and a negative return on equity of 508.89%. As a group, research analysts predict that Checkpoint Therapeutics, Inc. will post -5.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CKPT has been the subject of several analyst reports. HC Wainwright increased their price target on shares of Checkpoint Therapeutics from $26.00 to $76.00 and gave the company a “buy” rating in a research note on Friday, December 23rd. B. Riley upped their price objective on shares of Checkpoint Therapeutics from $7.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, December 19th.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CKPT. Morgan Jess S & Co. Inc. lifted its holdings in Checkpoint Therapeutics by 66.6% during the 3rd quarter. Morgan Jess S & Co. Inc. now owns 1,894,694 shares of the company’s stock worth $1,970,000 after buying an additional 757,372 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Checkpoint Therapeutics by 307.5% during the 1st quarter. Renaissance Technologies LLC now owns 923,035 shares of the company’s stock worth $1,634,000 after buying an additional 696,535 shares in the last quarter. Spotlight Asset Group Inc. acquired a new stake in Checkpoint Therapeutics during the 3rd quarter worth approximately $622,000. PVG Asset Management Corp acquired a new stake in Checkpoint Therapeutics during the 3rd quarter worth approximately $408,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Checkpoint Therapeutics during the 1st quarter worth approximately $292,000.

About Checkpoint Therapeutics

(Get Rating)

Checkpoint Therapeutics, Inc, clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.